Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft Source

Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update

Bone Marrow Transplantation volume 51, pages 1464–1469 (2016)Cite this article

Subjects

Abstract

Emerging data demonstrate promising results of related haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HCT) for the treatment of hematologic malignancies. Data about G-CSF primed PBSC as reliable source of graft with myeloablative conditioning are lacking. We updated the outcomes in 130 adult patients with high-risk hematologic malignancies who received haplo-PBSC transplantation consecutively under busulfan-based conditioning. PBSC were freshly isolated and infused without ex vivo T-cell depletion into the recipients. Myeloid recovery was achieved in 99.2% patients with full donor chimerism. The cumulative incidence of acute grade 3–4 GvHD, overall and extensive chronic GvHD was 14.9%, 38.6% and 16.5%, respectively. The 3-year non-relapse mortality rate was 24.1%. Non-remission prior to transplant was associated with higher incidence of relapse (P=0.006), inferior overall survival (P=0.017) and leukemia-free survival (P=0.024). These data suggest that PBSC is a reliable graft source in haploidentical, unmanipulated transplant settings under myeloablative conditioning in patients with high-risk hematologic malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  PubMed  Google Scholar 

  2. Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 2012; 97: 1523–1531.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in-vitro T-cell-depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119: 978–985.

    Article  PubMed  Google Scholar 

  4. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone marrow stem cell transplantation in haematological malignant diseases: a randomized trial. Lancet 2000; 355: 1231–1237.

    Article  CAS  PubMed  Google Scholar 

  6. Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005; 90: 643–648.

    CAS  PubMed  Google Scholar 

  7. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100: 3128–3134.

    Article  CAS  PubMed  Google Scholar 

  8. Meisel R, Klingebiel T, Dilloo D . Peripheral blood stem cells versus bone marrow in pediatric unrelated donor stem cell transplantation. Blood 2013; 121: 863–865.

    Article  CAS  PubMed  Google Scholar 

  9. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849–857.

    Article  CAS  PubMed  Google Scholar 

  10. Xu LP, Liu KY, Liu DH, Chen H, Han W, Chen YH et al. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/ haploidentical transplantation: a comparative analysis. Bone Marrow Transplant 2010; 45: 985–992.

    Article  CAS  PubMed  Google Scholar 

  11. Wenrong H, Honghua L, Gao C, Bo J, Wang Q, Yu Z et al. Unmanipulated HLA-mismatched/ haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies. Transfusion 2012; 52: 1354–1362.

    Article  Google Scholar 

  12. Luo Y, Hanwen X, Lai X, Shi J, Tan Y, Jingsong H et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 2014; 124: 2735–2743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.

    Article  CAS  PubMed  Google Scholar 

  14. Rowlings PA, Przepiorka D, Klein JP, GaLE RP, Passweg JR, henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855–864.

    Article  CAS  PubMed  Google Scholar 

  15. Castagna L, Crocchiolo R, Furst S, Bramanti S, EI Cheikh J, Sarina B et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014; 20: 724–729.

    Article  PubMed  Google Scholar 

  16. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 890–895.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow transplant 2012; 18: 1859–1866.

    Article  PubMed  Google Scholar 

  18. Chang YJ, Xu LP, Liu DH, Liu KY, Han W, Chen YH et al. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant 2009; 15: 632–638.

    Article  PubMed  Google Scholar 

  19. Kong Y, Hu Y, Zhang XH, Wang YZ, Mo XD, Zhang YY et al. Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1190–1197.

    Article  PubMed  Google Scholar 

  20. Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 2014; 124: 843–850.

    Article  CAS  PubMed  Google Scholar 

  21. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY et al. Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomized trial. Lancet Oncol 2010; 11: 331–338.

    Article  PubMed  Google Scholar 

  22. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487–1496.

    CAS  PubMed  Google Scholar 

  23. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 2012; 47: 1099–1104.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the laboratory teams and the nurses for their support to clinical work.

Author contributions

LY and D-HL were responsible for the conception and design of the study; W-RH, D-HL, FL, L-PD and LW collected, analyzed and interpreted the data; D-HL drafted the manuscript; W-RH, H-HL, C-JG, JB, FL, L-PD and YJ provided study material or patients; L-LW provided laboratory work.

Author information

Author notes

  1. W-R Huang and H-H Li: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Chinese PLA General Hospital, Beijing, China

    W-R Huang, H-H Li, C-J Gao, J Bo, F Li, L-P Dou, L-L Wang, Y Jing, L Wang, D-H Liu & L Yu

Authors
  1. W-R Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H-H Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C-J Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Bo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L-P Dou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L-L Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D-H Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to D-H Liu or L Yu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, WR., Li, HH., Gao, CJ. et al. Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update. Bone Marrow Transplant 51, 1464–1469 (2016). https://doi.org/10.1038/bmt.2016.166

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.166

This article is cited by

Search

Advanced search

Quick links